Even if treatments are cost-effective and relatively inexpensive, such as dexamethasone for patients with moderate-severe COVID-19, high burden of disease may have an extremely significant impact on the budget.
← all excerpts
Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
2
—
—
The sentences
This model compares the first two agents with randomized controlled trial data showing potential mortality benefit in moderate-severe COVID-19 infections, with remdesivir showing a statistical trend to survival in the preliminary report with a larger effect in patients with moderate infections and dexamethasone demonstrating a statistically significant benefit in both moderate and severe infections.